Table 4.
The key laboratory findings at the time of the diagnostic biopsy, clinical parameters and corticosteroid treatment time according to glomerular filtration rate below and above 90 ml/min/1.73 m2 at the latest follow-up
| eGFR < 90 ml/min/1.73 m2 n = 14 |
eGFR > 90 ml/min/1.73 m2 n = 38 |
p value | |
|---|---|---|---|
| Age at diagnosis, years | 13.8 (5.6–16.0) | 12.6 (1.8–16.9) | 0.10 |
| P-Cr at diagnosis, μmol/l | 192 (74–844) | 153 (47–1016) | 0.32 |
| eGFR at diagnosis, ml/min/1.73 m2 | 55 (13–95) | 46 (8–124) | 0.81 |
| ESR at diagnosis, mm/h | 95 (17–114), (n = 10) | 94 (9–140), (n = 35) | 0.56 |
| Haemoglobin, g/l | 107 (86–126) | 99 (85–129) | 0.45 |
| WBC, E9/l (n = 39) | 7.6 (5.9–10.6) | 8.9 (4.3–31.0) | 0.20 |
| Eosinophiles, E9/l (n = 39) | 0.27 (0.06–0.54) | 0.33 (0–0.69) | 0.38 |
| P-Pi, mmol/l (n = 33) | 0.85 (0.68–1.49) | 1.10 (0.78–2.27) | 0.15 |
| P-Urea, mmol/l (n = 49) | 7.1 (4.4–24.8) | 9.5 (4.7–32.7) | 0.19 |
| Glucosuria (n = 51) | 13 (100) | 35 (92) | 0.30 |
| Pyuria (n = 50) | 3 (23) | 13 (35) | 0.43 |
| Dialysis | 0 | 3 (8) | 0.28 |
| TINU (%) | 8 (57) | 25 (64) | 0.75 |
| Chronic uveitis, n (%) | 5 (33) | 16 (42) | 0.76 |
| Treatment delay, days | 44 (16-190) | 35 (11-173) | 0.67 |
| Corticosteroid therapy, n (%) | 13 (100) | 33 (85) | 0.12 |
| Duration of medication, months | 9.5 (0.1–15) | 6 (1–48) | 0.49 |
| Time to normal creatinine, months | 2.5 (1–14) | 1 (0–36) | 0.02 |
| Nephritis relapse, n (%) | 3 (23) | 9 (21) | 0.87 |
| Interstitial inflammation | 1 (0–3) | 2 (1–3) | 0.04 |
| Interstitial fibrosis gr. 1 | 3 (21) | 7 (18) | 0.81 |
| Tubular atrophy gr. 1 | 4 (29) | 10 (26) | 0.87 |
Data presented as n (%) or median (range) and analyses performed by Chi-squared or Kruskal–Wallis test, as appropriate. Two-tailed p value is reported. Number of subjects within group presented if missing cases. P-Cr, plasma creatinine; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; WBC, white blood cells; P–Pi, plasma phosphate concentration; TINU, tubulointerstitial nephritis and uveitis; treatment delay was defined as the time from onset of symptoms to the beginning of cortisone treatment